Trials / Completed
CompletedNCT01163851
Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin
A Phase 1 Study Evaluating The Pharmacokinetics And Pharmacodynamics Of Rn316 In Combination With Atorvastatin In Hypercholesterolemic Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin. PF-04950615 (RN316) is an investigational drug that is currently being studies as a cholesterol lowering therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 4 mg/kg | RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes. |
| BIOLOGICAL | 0.5 mg/kg | RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes. |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-02-01
- Completion
- 2011-04-01
- First posted
- 2010-07-16
- Last updated
- 2018-03-01
- Results posted
- 2015-05-07
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01163851. Inclusion in this directory is not an endorsement.